嗜麦芽寡养单胞菌药敏试验挑战与策略。
Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies.
机构信息
Pathology and Laboratory Medicine Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.
出版信息
J Clin Microbiol. 2021 Aug 18;59(9):e0109421. doi: 10.1128/JCM.01094-21.
Abstract
Stenotrophomonas maltophilia is intrinsically resistant to many beta-lactam antibiotics, including carbapenems, and is resistant to aminoglycosides, which limits the therapeutic repertoire for managing S. maltophilia infections. Additionally, employing automated susceptibility testing of S. maltophilia is challenging because commercial test systems' performance is limited (A. Khan, C. A. Arias, A. Abbott, J. Dien Bard, et al., J Clin Microbiol 59:e00654-21, 2021, https://doi.org/10.1128/JCM.00654-21). This commentary will briefly discuss the opportunity to use automated commercial susceptibility testing systems with S. maltophilia, with a focus on how to implement their use practically while mitigating risk of error.
摘要
嗜麦芽寡养单胞菌本质上对许多β-内酰胺类抗生素具有耐药性，包括碳青霉烯类，并且对氨基糖苷类药物具有耐药性，这限制了治疗嗜麦芽寡养单胞菌感染的治疗方案。此外，由于商业检测系统的性能有限，因此对嗜麦芽寡养单胞菌进行自动化药敏检测具有挑战性（A. Khan、C. A. Arias、A. Abbott、J. Dien Bard 等人，J Clin Microbiol 59:e00654-21，2021，https://doi.org/10.1128/JCM.00654-21）。本评论将简要讨论使用嗜麦芽寡养单胞菌的自动化商业药敏检测系统的机会，重点讨论如何在实际应用中实施这些系统，同时降低出错风险。
相似文献
1
Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies.
J Clin Microbiol. 2021 Aug 18;59(9):e0109421. doi: 10.1128/JCM.01094-21.
2
Stenotrophomonas maltophilia endogenous endophthalmitis: clinical presentation, sensitivity spectrum and management.
J Med Microbiol. 2009 Jun;58(Pt 6):837-838. doi: 10.1099/jmm.0.009431-0.
3
Review on : An Emerging Multidrug- resistant Opportunistic Pathogen.
Recent Pat Biotechnol. 2022;16(4):329-354. doi: 10.2174/1872208316666220512121205.
4
Stenotrophomonas maltophilia: An emerging opportunistic nosocomial pathogen in a tertiary care hospital in Al Batinah North Governorate, Oman.
Sultan Qaboos Univ Med J. 2021 Feb;21(1):e66-e71. doi: 10.18295/squmj.2021.21.01.009. Epub 2021 Mar 15.
5
Antibiotics resistance of Stenotrophomonas maltophilia strains isolated from various clinical specimens.
Afr Health Sci. 2016 Mar;16(1):149-52. doi: 10.4314/ahs.v16i1.20.
6
Steno-sphere: Navigating the enigmatic world of emerging multidrug-resistant Stenotrophomonas maltophilia.
Pharmacotherapy. 2023 Aug;43(8):833-846. doi: 10.1002/phar.2828. Epub 2023 Jun 8.
7
Drug Susceptibility Assessment in Stenotrophomonas Maltophilia Strains Isolated From the Blood of Organ Transplantation Recipients in a Warsaw Teaching Hospital During 2011 to 2014.
Transplant Proc. 2016 Jun;48(5):1411-3. doi: 10.1016/j.transproceed.2016.01.072.
8
Community-acquired infection due to Stenotrophomonas maltophilia: a rare cause of septic arthritis.
Turk J Pediatr. 2008 Jan-Feb;50(1):89-90.
9
Role of Stenotrophomonas maltophilia in hospital-acquired infection.
Br J Biomed Sci. 2005;62(3):145-54; quiz 1 p following 154. doi: 10.1080/09674845.2005.11732702.
10
Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).
Clin Infect Dis. 2001 May 15;32 Suppl 2:S104-13. doi: 10.1086/320183.
引用本文的文献
1
Isolation and characterization of novel bacteriophages targeting Stenotrophomonas maltophilia.
Sci Rep. 2025 Aug 13;15(1):29743. doi: 10.1038/s41598-025-14811-5.
2
Genomic analysis of contaminant Stenotrophomonas maltophilia, from placental swab culture, carrying antibiotic resistance: a potential hospital laboratory contaminant.
Sci Rep. 2025 Jul 1;15(1):22323. doi: 10.1038/s41598-025-07253-6.
3
Genomic and machine learning approaches to predict antimicrobial resistance in .
Microbiol Spectr. 2025 Aug 5;13(8):e0263224. doi: 10.1128/spectrum.02632-24. Epub 2025 Jun 18.
4
Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections.
Infect Dis Ther. 2025 Jun 6. doi: 10.1007/s40121-025-01170-x.
5
Clinical presentation and outcomes of bloodstream infection with intrinsically carbapenem-resistant non-fermenting gram-negative organisms: Stenotrophomonas maltophilia, Elizabethkingia spp. and Chryseobacterium spp. in Singapore, from 2012 to 2024.
BMC Infect Dis. 2025 Feb 25;25(1):273. doi: 10.1186/s12879-025-10636-9.
6
Understanding the rationale and clinical impact of the revised CLSI 2024 minocycline susceptibility breakpoints against Stenotrophomonas maltophilia.
Eur J Clin Microbiol Infect Dis. 2024 Dec;43(12):2453-2457. doi: 10.1007/s10096-024-04932-6. Epub 2024 Sep 19.
7
Epidemiology and antimicrobial resistance trends of pathogens causing urinary tract infections in Mwanza, Tanzania: A comparative study during and after the implementation of the National Action Plan on Antimicrobial Resistance (2017-2022).
Int J Infect Dis. 2024 Oct;147:107208. doi: 10.1016/j.ijid.2024.107208. Epub 2024 Aug 10.
8
Outbreak in an ICU: Investigation of Possible Routes of Transmission and Implementation of Infection Control Measures.
Pathogens. 2024 Apr 29;13(5):369. doi: 10.3390/pathogens13050369.
9
A simple solid media assay for detection of synergy between bacteriophages and antibiotics.
Microbiol Spectr. 2024 May 2;12(5):e0322123. doi: 10.1128/spectrum.03221-23. Epub 2024 Mar 25.
10
Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.
Ann Clin Microbiol Antimicrob. 2024 Mar 19;23(1):26. doi: 10.1186/s12941-024-00685-4.
本文引用的文献
1
Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia.
J Clin Microbiol. 2021 Aug 18;59(9):e0065421. doi: 10.1128/JCM.00654-21.
2
Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for .
Antimicrob Agents Chemother. 2023 May 1;95(5). doi: 10.1128/AAC.02631-20. Epub 2021 Feb 8.
3
Activity and Efficacy of Cefiderocol against Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.01436-20.
4
Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints.
Clin Infect Dis. 2020 Dec 3;71(9):e523-e529. doi: 10.1093/cid/ciaa121.
5
Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.
Clin Infect Dis. 2020 Aug 14;71(4):1095-1098. doi: 10.1093/cid/ciz1155.
6
Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study.
Crit Care. 2019 Nov 21;23(1):371. doi: 10.1186/s13054-019-2649-5.
7
Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01603-19.
8
Comparative Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against in the Murine Thigh Model.
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01558-19. Epub 2019 Oct 7.
9
Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia.
J Antimicrob Chemother. 2019 Jul 1;74(7):2055-2059. doi: 10.1093/jac/dkz116.
10
Antimicrobial Susceptibility of Complex and Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016).
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S34-S46. doi: 10.1093/ofid/ofy293. eCollection 2019 Mar.
Zotero 插件